{"id":5477,"date":"2022-11-21T11:37:00","date_gmt":"2022-11-21T11:37:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/"},"modified":"2025-05-27T12:04:00","modified_gmt":"2025-05-27T10:04:00","slug":"teplizumab-goedgekeurd-door-fda-in-amerika","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/","title":{"rendered":"Teplizumab goedgekeurd door FDA in Amerika"},"content":{"rendered":"

Afgelopen vrijdag is het medicijn teplizumab goedgekeurd dat het begin van type 1 diabetes tot ongeveer 2 jaar kan vertragen door de Amerikaanse Food and Drug Administration (FDA).<\/a> Voor het eerst in de geschiedenis is er een goedgekeurde therapie die het auto immuun systeem achter type 1 diabetes (T1D) aanpakt.
<\/h4>\n

Teplizumab zorgt ervoor dat de insulineproducerende cellen niet meer worden aangevallen. Tegelijk help het om het aantal cellen dat de immuunrespons matigt, te doen toenemen. Het wordt gedurende 14 dagen achter elkaar 1 keer per dag via een infuus toegediend.<\/p>\n

Voor wie geschikt?<\/strong><\/p>\n

Studies hebben aangetoond dat het medicijn het begin van type 1 diabetes (bekend als klinische T1D) maanden tot maximaal twee jaar kan vertragen bij volwassenen en kinderen van 8 jaar en ouder die momenteel stadium 2 type 1 diabetes hebben. Dat betekent dat zij nog geen klinische symptomen van T1D hebben, maar wel tekenen vertonen van een auto-immuunaanval en verlies van insulineproducerende cellen waardoor hun bloedglucose abnormaal begint te worden. Ze zijn in dit stadium nog niet insulineafhankelijk. <\/p>\n

Wat betekent dit?<\/strong><\/p>\n

Aaron Kowalski, Ph.D., CEO van Breakthrough T1D International, geeft aan dat \u201cdeze beslissing mensen die het risico lopen type 1 diabetes te ontwikkelen, tijd schenkt. Voor het eerst hebben we een manier om de koers te veranderen en de ontwikkeling van type 1 diabetes te vertragen.”<\/p>\n

\u201cDit is een enorme overwinning voor de community en het nieuwste voorbeeld van hoe het onderzoek en de belangenbehartiging van Breakthrough T1D bijdragen aan het verbeteren van levens van vandaag en morgen. Ik ben enorm trots op de rol die Breakthrough T1D heeft gespeeld bij het op de markt brengen van deze therapie, en we kijken ernaar uit om met andere belanghebbenden samen te werken om ervoor te zorgen dat teplizumab toegankelijk is voor degenen die het nodig hebben.\u201d<\/p>\n

Onderzoek<\/strong><\/p>\n

Dit is het resultaat van tientallen jaren van Breakthrough T1D-werk en investeringen in het onderzoek, te beginnen met onderzoek in een vroeg stadium in de jaren tachtig en aanvullende financiering in 2017. Lees hier meer over de bijdrage die Breakthrough T1D Internationaal heeft geleverd (engelstalig).<\/a><\/p>\n

In Amerika is Teplizumab nu goedgekeurd. In Nederland zijn we nog niet zo ver. Breakthrough T1D Nederland werkt samen met Breakthrough T1D International collega’s, onderzoekers en partners in Nederland om dit medicijn zo snel mogelijk ook beschikbaar te krijgen in Nederland. <\/p>","protected":false,"raw":""},"excerpt":{"rendered":"

Afgelopen vrijdag is het medicijn teplizumab goedgekeurd dat het begin van type 1 diabetes tot ongeveer 2 jaar kan vertragen door de Amerikaanse Food and Drug Administration (FDA). Voor het eerst in de geschiedenis is er een goedgekeurde therapie die het auto immuun systeem achter type 1 diabetes (T1D) aanpakt. Teplizumab zorgt ervoor dat de […]<\/p>\n","protected":false},"author":1,"featured_media":5478,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184,195],"tags":[],"class_list":["post-5477","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-archief","category-voorkomen"],"yoast_head":"\nTeplizumab goedgekeurd door FDA in Amerika - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teplizumab goedgekeurd door FDA in Amerika - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Afgelopen vrijdag is het medicijn teplizumab goedgekeurd dat het begin van type 1 diabetes tot ongeveer 2 jaar kan vertragen door de Amerikaanse Food and Drug Administration (FDA). Voor het eerst in de geschiedenis is er een goedgekeurde therapie die het auto immuun systeem achter type 1 diabetes (T1D) aanpakt. Teplizumab zorgt ervoor dat de […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-21T11:37:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-27T10:04:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2022\/11\/betacel-icoon-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Teplizumab goedgekeurd door FDA in Amerika\",\"datePublished\":\"2022-11-21T11:37:00+00:00\",\"dateModified\":\"2025-05-27T10:04:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/\"},\"wordCount\":392,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2022\/11\/betacel-icoon-3.jpg\",\"articleSection\":[\"Archief\",\"Voorkomen\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/\",\"name\":\"Teplizumab goedgekeurd door FDA in Amerika - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2022\/11\/betacel-icoon-3.jpg\",\"datePublished\":\"2022-11-21T11:37:00+00:00\",\"dateModified\":\"2025-05-27T10:04:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#primaryimage\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2022\/11\/betacel-icoon-3.jpg\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2022\/11\/betacel-icoon-3.jpg\",\"width\":700,\"height\":500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teplizumab goedgekeurd door FDA in Amerika\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Teplizumab goedgekeurd door FDA in Amerika - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/","og_locale":"nl_NL","og_type":"article","og_title":"Teplizumab goedgekeurd door FDA in Amerika - Breakthrough T1D","og_description":"Afgelopen vrijdag is het medicijn teplizumab goedgekeurd dat het begin van type 1 diabetes tot ongeveer 2 jaar kan vertragen door de Amerikaanse Food and Drug Administration (FDA). Voor het eerst in de geschiedenis is er een goedgekeurde therapie die het auto immuun systeem achter type 1 diabetes (T1D) aanpakt. Teplizumab zorgt ervoor dat de […]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/","og_site_name":"Breakthrough T1D","article_published_time":"2022-11-21T11:37:00+00:00","article_modified_time":"2025-05-27T10:04:00+00:00","og_image":[{"width":700,"height":500,"url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2022\/11\/betacel-icoon-3.jpg","type":"image\/jpeg"}],"author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin","Geschatte leestijd":"2 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Teplizumab goedgekeurd door FDA in Amerika","datePublished":"2022-11-21T11:37:00+00:00","dateModified":"2025-05-27T10:04:00+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/"},"wordCount":392,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#primaryimage"},"thumbnailUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2022\/11\/betacel-icoon-3.jpg","articleSection":["Archief","Voorkomen"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/","name":"Teplizumab goedgekeurd door FDA in Amerika - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#primaryimage"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#primaryimage"},"thumbnailUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2022\/11\/betacel-icoon-3.jpg","datePublished":"2022-11-21T11:37:00+00:00","dateModified":"2025-05-27T10:04:00+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#primaryimage","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2022\/11\/betacel-icoon-3.jpg","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2022\/11\/betacel-icoon-3.jpg","width":700,"height":500},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/teplizumab-goedgekeurd-door-fda-in-amerika\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Teplizumab goedgekeurd door FDA in Amerika"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5477"}],"version-history":[{"count":2,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5477\/revisions"}],"predecessor-version":[{"id":10014,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5477\/revisions\/10014"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media\/5478"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}